{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:51:15Z","timestamp":1780779075946,"version":"3.54.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Young and Middle-Aged Discipline Leaders of Henan Health Commission","award":["HNSWJW-2020021"],"award-info":[{"award-number":["HNSWJW-2020021"]}]},{"name":"the First Affiliated Hospital of Wannan Medical College introduced talents special","award":["KY28880624"],"award-info":[{"award-number":["KY28880624"]}]},{"name":"the Anhui Province Clinical medical research transformation project","award":["202204295107020011"],"award-info":[{"award-number":["202204295107020011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"DOI":"10.1186\/s40001-025-03363-z","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T03:13:02Z","timestamp":1762744382000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Unveiling prognostic biomarkers and immunotherapeutic insights in prostate cancer through multi-omics and machine learning"],"prefix":"10.1186","volume":"30","author":[{"given":"Huarui","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawang","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zechen","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"3","key":"3363_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3363_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00243-0","volume":"7","author":"RJ Rebello","year":"2021","unstructured":"Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"3363_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202200997","volume":"6","author":"X Mou","year":"2022","unstructured":"Mou X, Wu Q, Zhang Z, Liu Y, Zhang J, Zhang C, et al. Nanozymes for regenerative medicine. Small Methods. 2022;6(11):e2200997.","journal-title":"Small Methods"},{"issue":"6","key":"3363_CR4","first-page":"1194","volume":"55","author":"X Lin","year":"2019","unstructured":"Lin X, Kapoor A, Gu Y, Chow MJ, Xu H, Major P, et al. Assessment of biochemical recurrence of prostate cancer (Review). Int J Oncol. 2019;55(6):1194\u2013212.","journal-title":"Int J Oncol"},{"issue":"8","key":"3363_CR5","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.cell.2023.02.039","volume":"186","author":"OK Dagher","year":"2023","unstructured":"Dagher OK, Schwab RD, Brookens SK, Posey AD Jr. Advances in cancer immunotherapies. Cell. 2023;186(8):1814-1814.e1811.","journal-title":"Cell"},{"issue":"8","key":"3363_CR6","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1158\/0008-5472.CAN-19-2948","volume":"80","author":"HR Cha","year":"2020","unstructured":"Cha HR, Lee JH, Ponnazhagan S. Revisiting immunotherapy: a focus on prostate cancer. Cancer Res. 2020;80(8):1615\u201323.","journal-title":"Cancer Res"},{"key":"3363_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-023-00690-2","author":"J Liu","year":"2023","unstructured":"Liu J, Kadier A, Guo Y, Zhang W, Chen H, Zhang Z, et al. Effect of tumor CD276 expression on infiltrating immune cells and clinicopathological features of prostate cancer. Prostate Cancer Prostatic Dis. 2023. https:\/\/doi.org\/10.1038\/s41391-023-00690-2.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3363_CR8","doi-asserted-by":"crossref","unstructured":"Hennrich U, Eder M: [(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals (Basel). 2021;14(8).","DOI":"10.3390\/ph14080713"},{"issue":"1","key":"3363_CR9","volume":"11","author":"DC Feng","year":"2024","unstructured":"Feng DC, Zhu WZ, Wang J, Li DX, Shi X, Xiong Q, et al. The implications of single-cell RNA-seq analysis in prostate cancer: unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Mil Med Res. 2024;11(1):21.","journal-title":"Mil Med Res"},{"issue":"1","key":"3363_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-023-00407-0","volume":"12","author":"S Xin","year":"2023","unstructured":"Xin S, Liu X, Li Z, Sun X, Wang R, Zhang Z, et al. Scrna-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer. Exp Hematol Oncol. 2023;12(1):49.","journal-title":"Exp Hematol Oncol"},{"issue":"13","key":"3363_CR11","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1158\/0008-5472.CAN-25-0269","volume":"85","author":"M Smelik","year":"2025","unstructured":"Smelik M, Diaz-Roncero Gonzalez D, An X, Heer R, Henningsohn L, Li X, et al. Combining spatial transcriptomics, pseudotime, and machine learning enables discovery of biomarkers for prostate cancer. Cancer Res. 2025;85(13):2514\u201326.","journal-title":"Cancer Res"},{"key":"3363_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.814813","volume":"9","author":"XY Li","year":"2021","unstructured":"Li XY, You JX, Zhang LY, Su LX, Yang XT. A novel model based on necroptosis-related genes for predicting prognosis of patients with prostate adenocarcinoma. Front Bioeng Biotechnol. 2021;9:814813.","journal-title":"Front Bioeng Biotechnol"},{"key":"3363_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.605810","volume":"11","author":"K Guo","year":"2021","unstructured":"Guo K, Lai C, Shi J, Tang Z, Liu C, Li K, et al. A novel risk factor model based on glycolysis-associated genes for predicting the prognosis of patients with prostate cancer. Front Oncol. 2021;11:605810.","journal-title":"Front Oncol"},{"key":"3363_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.974034","volume":"13","author":"L Jin","year":"2022","unstructured":"Jin L, Mei W, Liu X, Sun X, Xin S, Zhou Z, et al. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer. Front Immunol. 2022;13:974034.","journal-title":"Front Immunol"},{"issue":"4","key":"3363_CR15","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.eururo.2017.10.036","volume":"73","author":"V Cucchiara","year":"2018","unstructured":"Cucchiara V, Cooperberg MR, Dall\u2019Era M, Lin DW, Montorsi F, Schalken JA, et al. Genomic markers in prostate cancer decision making. Eur Urol. 2018;73(4):572\u201382.","journal-title":"Eur Urol"},{"key":"3363_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aah3560","author":"W Roh","year":"2017","unstructured":"Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017. https:\/\/doi.org\/10.1126\/scitranslmed.aah3560.","journal-title":"Sci Transl Med"},{"issue":"5","key":"3363_CR17","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1002\/cam4.2120","volume":"8","author":"YC Hsu","year":"2019","unstructured":"Hsu YC, Chang YH, Chang GC, Ho BC, Yuan SS, Li YC, et al. Tumor mutation burden and recurrent tumors in hereditary lung cancer. Cancer Med. 2019;8(5):2179\u201387.","journal-title":"Cancer Med"},{"issue":"3","key":"3363_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2019.11.010","volume":"31","author":"R Barroso-Sousa","year":"2020","unstructured":"Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020;31(3):387\u201394.","journal-title":"Ann Oncol"},{"issue":"12","key":"3363_CR19","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.trecan.2021.08.005","volume":"7","author":"M Merchant","year":"2021","unstructured":"Merchant M, Ranjan A, Pang Y, Yu G, Kim O, Khan J, et al. Tumor mutational burden and immunotherapy in gliomas. Trends Cancer. 2021;7(12):1054\u20138.","journal-title":"Trends Cancer"},{"key":"3363_CR20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.71880","author":"C Yang","year":"2022","unstructured":"Yang C, Zhang H, Chen M, Wang S, Qian R, Zhang L, et al. A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. Elife. 2022. https:\/\/doi.org\/10.7554\/eLife.71880.","journal-title":"Elife"},{"issue":"1","key":"3363_CR21","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41556-020-00613-6","volume":"23","author":"S Chen","year":"2021","unstructured":"Chen S, Zhu G, Yang Y, Wang F, Xiao YT, Zhang N, et al. Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol. 2021;23(1):87\u201398.","journal-title":"Nat Cell Biol"},{"issue":"5","key":"3363_CR22","first-page":"1","volume":"50","author":"GY Lee","year":"2018","unstructured":"Lee GY, Shin SH, Shin HW, Chun YS, Park JW. Ndrg3 lowers the metastatic potential in prostate cancer as a feedback controller of hypoxia-inducible factors. Exp Mol Med. 2018;50(5):1\u201313.","journal-title":"Exp Mol Med"},{"issue":"5","key":"3363_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41585-019-0171-9","volume":"16","author":"JC Penticuff","year":"2019","unstructured":"Penticuff JC, Woolbright BL, Sielecki TM, Weir SJ, Taylor JA 3rd. MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential. Nat Rev Urol. 2019;16(5):318\u201328.","journal-title":"Nat Rev Urol"},{"key":"3363_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.574394","volume":"8","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Song H, Jiang L, Qiao Y, Yang D, Wang D, et al. Silybin prevents prostate cancer by inhibited the ALDH1A1 expression in the retinol metabolism pathway. Front Cell Dev Biol. 2020;8:574394.","journal-title":"Front Cell Dev Biol"},{"key":"3363_CR25","volume":"26","author":"SN Joshi","year":"2021","unstructured":"Joshi SN, Murphy EA, Olaniyi P, Bryant RJ. The multiple effects of aspirin in prostate cancer patients. Cancer Treat Res Commun. 2021;26:100267.","journal-title":"Cancer Treat Res Commun"},{"key":"3363_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814212","author":"LM Harbin","year":"2023","unstructured":"Harbin LM, Lin N, Ueland FR, Kolesar JM. SYNE1 mutation is associated with increased tumor mutation burden and immune cell infiltration in ovarian cancer. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241814212.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3363_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-018-1002-1","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on immunogenomic profiling. J Exp Clin Cancer Res. 2018;37(1):327.","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"3363_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1\u201310.","journal-title":"Immunity"},{"key":"3363_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002949","author":"N Kl\u00fcmper","year":"2021","unstructured":"Kl\u00fcmper N, Ralser DJ, Zarbl R, Schlack K, Schrader AJ, Rehlinghaus M, et al. CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002949.","journal-title":"J Immunother Cancer"},{"issue":"12","key":"3363_CR30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1136\/thoraxjnl-2020-215614","volume":"77","author":"SS Kanabar","year":"2022","unstructured":"Kanabar SS, Tiwari A, Soran V, Balendran P, Price M, Turner AM. Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. Thorax. 2022;77(12):1163\u201374.","journal-title":"Thorax"},{"issue":"4","key":"3363_CR31","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2018.78.2276","volume":"37","author":"PA Ott","year":"2019","unstructured":"Ott PA, Bang YJ, Piha-Paul SA, Razak ARA, Bennouna J, Soria JC, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318\u201327.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3363_CR32","doi-asserted-by":"publisher","first-page":"714","DOI":"10.7150\/thno.88057","volume":"14","author":"I Gorodetska","year":"2024","unstructured":"Gorodetska I, Offermann A, P\u00fcschel J, Lukiyanchuk V, Gaete D, Kurzyukova A, et al. ALDH1A1 drives prostate cancer metastases and radioresistance by interplay with AR- and RAR-dependent transcription. Theranostics. 2024;14(2):714\u201337.","journal-title":"Theranostics"},{"issue":"2","key":"3363_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bbrc.2020.02.098","volume":"525","author":"Z Ma","year":"2020","unstructured":"Ma Z, Chao F, Wang S, Song Z, Zhuo Z, Zhang J, et al. CTHRC1 affects malignant tumor cell behavior and is regulated by miR-30e-5p in human prostate cancer. Biochem Biophys Res Commun. 2020;525(2):418\u201324.","journal-title":"Biochem Biophys Res Commun"},{"key":"3363_CR34","doi-asserted-by":"publisher","DOI":"10.34133\/research.0313","volume":"7","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Hu X, Yu H, Sun H, Zhang L, Shao C. The FTO mediated N6-methyladenosine modification of DDIT4 regulation with tumorigenesis and metastasis in prostate cancer. Research. 2024;7:0313.","journal-title":"Research"},{"issue":"7","key":"3363_CR35","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s12033-021-00326-7","volume":"63","author":"Z Zhang","year":"2021","unstructured":"Zhang Z. Mir-124-3p suppresses prostatic carcinoma by targeting PTGS2 through the AKT\/NF-\u03baB pathway. Mol Biotechnol. 2021;63(7):621\u201330.","journal-title":"Mol Biotechnol"},{"issue":"14","key":"3363_CR36","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/pros.20803","volume":"68","author":"KM Haram","year":"2008","unstructured":"Haram KM, Peltier HJ, Lu B, Bhasin M, Otu HH, Choy B, et al. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy. Prostate. 2008;68(14):1517\u201330.","journal-title":"Prostate"},{"issue":"1","key":"3363_CR37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jamaoncol.2020.6045","volume":"7","author":"DW Lin","year":"2021","unstructured":"Lin DW, Nelson PS. Prognostic genomic biomarkers in patients with localized prostate cancer: is rising utilization justified by evidence? JAMA Oncol. 2021;7(1):59\u201360.","journal-title":"JAMA Oncol"},{"issue":"6","key":"3363_CR38","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75(6):967\u201387.","journal-title":"Eur Urol"},{"issue":"11","key":"3363_CR39","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/15384101.2023.2206502","volume":"22","author":"SP Pitzen","year":"2023","unstructured":"Pitzen SP, Dehm SM. Basal epithelial cells in prostate development, tumorigenesis, and cancer progression. Cell Cycle. 2023;22(11):1303\u201318.","journal-title":"Cell Cycle"},{"key":"3363_CR40","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cellsig.2019.01.006","volume":"57","author":"SS Jankauskas","year":"2019","unstructured":"Jankauskas SS, Wong DWL, Bucala R, Djudjaj S, Boor P. Evolving complexity of MIF signaling. Cell Signal. 2019;57:76\u201388.","journal-title":"Cell Signal"},{"issue":"1","key":"3363_CR41","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s12935-022-02691-y","volume":"22","author":"N Gholami","year":"2022","unstructured":"Gholami N, Haghparast A, Alipourfard I, Nazari M. Prostate cancer in omics era. Cancer Cell Int. 2022;22(1):274.","journal-title":"Cancer Cell Int"},{"issue":"17","key":"3363_CR42","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.1158\/0008-5472.CAN-21-1392","volume":"81","author":"LA Sena","year":"2021","unstructured":"Sena LA, Denmeade SR. Fatty acid synthesis in prostate cancer: vulnerability or epiphenomenon? Cancer Res. 2021;81(17):4385\u201393.","journal-title":"Cancer Res"},{"issue":"16","key":"3363_CR43","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/0008-5472.CAN-16-0903","volume":"76","author":"KH Stopsack","year":"2016","unstructured":"Stopsack KH, Gerke TA, Sinnott JA, Penney KL, Tyekucheva S, Sesso HD, et al. Cholesterol metabolism and prostate cancer lethality. Cancer Res. 2016;76(16):4785\u201390.","journal-title":"Cancer Res"},{"issue":"3","key":"3363_CR44","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.5394","volume":"5","author":"RP Graf","year":"2022","unstructured":"Graf RP, Fisher V, Weberpals J, Gjoerup O, Tierno MB, Huang RSP, et al. Comparative effectiveness of immune checkpoint inhibitors vs chemotherapy by tumor mutational burden in metastatic castration-resistant prostate cancer. JAMA Netw Open. 2022;5(3):e225394.","journal-title":"JAMA Netw Open"},{"issue":"18","key":"3363_CR45","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-18-0653","volume":"24","author":"AM Blee","year":"2018","unstructured":"Blee AM, He Y, Yang Y, Ye Z, Yan Y, Pan Y, et al. TMPRSS2-ERG controls luminal epithelial lineage and antiandrogen sensitivity in pten and tp53-mutated prostate cancer. Clin Cancer Res. 2018;24(18):4551\u201365.","journal-title":"Clin Cancer Res"},{"issue":"695","key":"3363_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adf6724","volume":"15","author":"W Shi","year":"2023","unstructured":"Shi W, Wang Y, Zhao Y, Kim JJ, Li H, Meng C, et al. Immune checkpoint B7\u2013H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Sci Transl Med. 2023;15(695):eadf6724.","journal-title":"Sci Transl Med"},{"issue":"5","key":"3363_CR47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrclinonc.2018.27","volume":"15","author":"JC Del Paggio","year":"2018","unstructured":"Del Paggio JC. Immunotherapy: cancer immunotherapy and the value of cure. Nat Rev Clin Oncol. 2018;15(5):268\u201370.","journal-title":"Nat Rev Clin Oncol"},{"key":"3363_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217155","volume":"601","author":"D Liu","year":"2024","unstructured":"Liu D, Wang L, Guo Y. Advances in and prospects of immunotherapy for prostate cancer. Cancer Lett. 2024;601:217155.","journal-title":"Cancer Lett"},{"issue":"1","key":"3363_CR49","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.eururo.2022.02.023","volume":"82","author":"EY Yu","year":"2022","unstructured":"Yu EY, Kolinsky MP, Berry WR, Retz M, Mourey L, Piulats JM, et al. Pembrolizumab plus docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer: long-term results from the phase 1b\/2 KEYNOTE-365 cohort B study. Eur Urol. 2022;82(1):22\u201330.","journal-title":"Eur Urol"},{"issue":"1","key":"3363_CR50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","volume":"28","author":"T Powles","year":"2022","unstructured":"Powles T, Yuen KC, Gillessen S, Kadel EE 3rd, Rathkopf D, Matsubara N, et al. Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nat Med. 2022;28(1):144\u201353.","journal-title":"Nat Med"},{"issue":"8","key":"3363_CR51","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1038\/s41416-024-02614-w","volume":"130","author":"C Eberlein","year":"2024","unstructured":"Eberlein C, Williamson SC, Hopcroft L, Ros S, Moss JI, Kerr J, et al. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer. Br J Cancer. 2024;130(8):1377\u201387.","journal-title":"Br J Cancer"},{"key":"3363_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137268","author":"J Jin","year":"2024","unstructured":"Jin J, Guo Q, Yan Z. The role of Lutheran\/basal cell adhesion molecule in hematological diseases and tumors. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25137268.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3363_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13148-022-01319-2","volume":"14","author":"J Zhao","year":"2022","unstructured":"Zhao J, Liang J, Yang Y, Sun G, Zhang X, Zhao J, et al. Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma. Clin Epigenetics. 2022;14(1):99.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"3363_CR54","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1186\/s12935-021-02266-3","volume":"21","author":"D Peng","year":"2021","unstructured":"Peng D, Wei C, Zhang X, Li S, Liang H, Zheng X, et al. Pan-cancer analysis combined with experiments predicts CTHRC1 as a therapeutic target for human cancers. Cancer Cell Int. 2021;21(1):566.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"3363_CR55","first-page":"69","volume":"18","author":"O Tysoe","year":"2022","unstructured":"Tysoe O. Ddit4 contributes to macrophage reprogramming. Nat Rev Endocrinol. 2022;18(2):69.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"3363_CR56","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1172\/JCI127755","volume":"129","author":"N Markosyan","year":"2019","unstructured":"Markosyan N, Li J, Sun YH, Richman LP, Lin JH, Yan F, et al. Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). J Clin Invest. 2019;129(9):3594\u2013609.","journal-title":"J Clin Invest"},{"key":"3363_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-020-09280-z","volume":"17","author":"D Shin","year":"2020","unstructured":"Shin D, Park J, Han D, Moon JH, Ryu HS, Kim Y. Identification of TUBB2A by quantitative proteomic analysis as a novel biomarker for the prediction of distant metastatic breast cancer. Clin Proteomics. 2020;17:16.","journal-title":"Clin Proteomics"},{"issue":"1","key":"3363_CR58","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40364-022-00393-1","volume":"10","author":"H Yin","year":"2022","unstructured":"Yin H, Qin H, Yang L, Chen M, Yang Y, Zhang W, et al. CircCYP24A1 promotes docetaxel resistance in prostate cancer by upregulating ALDH1A3. Biomark Res. 2022;10(1):48.","journal-title":"Biomark Res"},{"key":"3363_CR59","doi-asserted-by":"crossref","unstructured":"Magrassi L, Pinton G, Luzzi S, Comincini S, Scravaglieri A, Gigliotti V, Bernardoni BL, D'Agostino I, Juretich F, La Motta C, et al. A new vista of aldehyde dehydrogenase 1A3 (ALDH1A3): new specific inhibitors and activity-based probes targeting ALDH1A3 dependent pathways in glioblastoma, mesothelioma and other cancers. Cancers (Basel). 2024;16(13).","DOI":"10.3390\/cancers16132397"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03363-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-025-03363-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-025-03363-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:03:42Z","timestamp":1762787022000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-025-03363-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3363"],"URL":"https:\/\/doi.org\/10.1186\/s40001-025-03363-z","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The research involving human participants was approved by the Ethics Committee for Scientific Research and New Technologies of the First Affiliated Hospital of Wannan Medical College, and informed consent was obtained from all individual participants whose identifying information is included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1093"}}